| Q34677347 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib |
| Q57911301 | Acute heart failure: lessons learned, roads ahead |
| Q57175195 | Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome |
| Q90656623 | An international consensus statement on the management of postoperative anaemia after major surgical procedures |
| Q96823829 | Anaemia, iron deficiency and heart failure in 2020: facts and numbers |
| Q89307259 | Anemia in heart failure - from guidelines to controversies and challenges |
| Q41704746 | Anemia in severe heart failure patients: does it predict prognosis? |
| Q38944812 | Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure. |
| Q87737241 | April 2017 at a glance: cardiomyopathies and clinical trials |
| Q97071836 | Association of iron deficiency, anaemia, and functional outcomes in patients undergoing edge-to-edge mitral valve repair |
| Q58563608 | Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores |
| Q90578720 | Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. |
| Q41686268 | Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC). |
| Q92291935 | ESC Heart Failure receives its first impact factor |
| Q38374099 | Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency |
| Q92426359 | Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy |
| Q91620336 | Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial |
| Q36354815 | Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis |
| Q88035892 | Ferric Carboxymaltose: A Review in Iron Deficiency |
| Q91793634 | Haemodynamic Effects of Anaemia in Patients with Acute Decompensated Heart Failure |
| Q64890054 | Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. |
| Q56210548 | Heart failure |
| Q57864463 | Heart failure and co-morbidity revisited; the elephant in the room |
| Q101041624 | High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality |
| Q89839189 | Iatrogenic Decompensated Heart Failure |
| Q38668459 | Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. |
| Q58078885 | Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study |
| Q57628371 | Improving Postdischarge Outcomes in Acute Heart Failure |
| Q90259003 | Influence of mitochondrial and systemic iron levels in heart failure pathology |
| Q50100379 | Intravenous ferric carboxymaltose for heart failure with iron deficiency |
| Q92214661 | Intravenous iron supplementation is state of the art therapy in patients with heart failure and iron deficiency |
| Q91918348 | Intravenous iron therapy for patients with heart failure: expanding body of evidence |
| Q92446436 | Intravenous iron therapy in heart failure: a different perspective |
| Q38751844 | Investigation and treatment for iron deficiency in heart failure: the unmet need in Lower and Middle Income Countries |
| Q38637837 | Iron Deficiency in Heart Failure: Efficacy and safety of intravenous iron therapy. |
| Q90303762 | Iron Deficiency in Heart Failure: to Treat or Not to Treat? |
| Q64111473 | Iron Metabolism: An Emerging Therapeutic Target in Critical Illness |
| Q89071688 | Iron Therapy in Heart Failure: Ready for Primetime? |
| Q33700880 | Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners |
| Q90672995 | Iron and Heart Failure: Diagnosis, Therapies, and Future Directions |
| Q39371536 | Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management |
| Q38848629 | Iron deficiency and red cell indices in patients with heart failure |
| Q49563077 | Iron deficiency and red cell indices in patients with heart failure: reply |
| Q58764012 | Iron deficiency as energetic insult to skeletal muscle in chronic diseases |
| Q59329679 | Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: an observational prospective study on 1161 patients |
| Q90577509 | Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study |
| Q56968591 | Iron deficiency in chronic heart failure: case-based practical guidance |
| Q87892834 | Ironing out iron deficiency in heart failure |
| Q49503072 | January 2018 at a glance: biomarkers, co-morbidities and mechanical circulatory support |
| Q87925073 | July 2016 at a glance: the critical role of co-morbidities |
| Q89392719 | March 2017 at a glance: pathophysiology, imaging, biomarkers and devices |
| Q38759545 | Mitochondrial Therapies in Heart Failure |
| Q92462134 | Monitoring of iron status in patients with heart failure |
| Q64051952 | New drugs: big changes in conservative heart failure therapy? |
| Q26741764 | Nutritional Deficiency in Patients with Heart Failure |
| Q57045923 | Patient-reported and morbidity-mortality endpoints: can one have the best of both worlds? |
| Q89071685 | Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure |
| Q47225343 | Postoperative outcomes following cardiac surgery in non-anaemic iron-replete and iron-deficient patients - an exploratory study. |
| Q99208896 | Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial |
| Q33720452 | Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry |
| Q52617061 | Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. |
| Q64120958 | Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry |
| Q50048824 | Publishing in a heart failure journal-where lies the scientific interest? |
| Q57282391 | Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data |
| Q92293076 | Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failur |
| Q92670169 | Recent advances in the treatment of chronic heart failure |
| Q89675911 | Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial |
| Q92353984 | Saudi Heart Association (SHA) guidelines for the management of heart failure |
| Q57470916 | Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice |
| Q99567507 | Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology |
| Q100516700 | Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial |
| Q49972496 | Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF) |
| Q92316609 | The difference in referencing in Web of Science, Scopus, and Google Scholar |
| Q39409288 | Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic? |
| Q52740209 | Trace minerals intake: Risks and benefits for cardiovascular health. |
| Q60943112 | Updates in heart failure: what last year brought to us |
| Q52838800 | [Iron deficiency : Recognition and treatment]. |